Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs

EBioMedicine. 2022 Jan:75:103812. doi: 10.1016/j.ebiom.2022.103812. Epub 2022 Jan 13.

Abstract

Background: Thromboembolism is a life-threatening manifestation of coronavirus disease 2019 (COVID-19). We investigated a dysfunctional phenotype of vascular endothelial cells in the lungs during COVID-19.

Methods: We obtained the lung specimens from the patients who died of COVID-19. The phenotype of endothelial cells and immune cells was examined by flow cytometry and immunohistochemistry (IHC) analysis. We tested the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the endothelium using IHC and electron microscopy.

Findings: The autopsy lungs of COVID-19 patients exhibited severe coagulation abnormalities, immune cell infiltration, and platelet activation. Pulmonary endothelial cells of COVID-19 patients showed increased expression of procoagulant von Willebrand factor (VWF) and decreased expression of anticoagulants thrombomodulin and endothelial protein C receptor (EPCR). In the autopsy lungs of COVID-19 patients, the number of macrophages, monocytes, and T cells was increased, showing an activated phenotype. Despite increased immune cells, adhesion molecules such as ICAM-1, VCAM-1, E-selectin, and P-selectin were downregulated in pulmonary endothelial cells of COVID-19 patients. Notably, decreased thrombomodulin expression in endothelial cells was associated with increased immune cell infiltration in the COVID-19 patient lungs. There were no SARS-CoV-2 particles detected in the lung endothelium of COVID-19 patients despite their dysfunctional phenotype. Meanwhile, the autopsy lungs of COVID-19 patients showed SARS-CoV-2 virions in damaged alveolar epithelium and evidence of hypoxic injury.

Interpretation: Pulmonary endothelial cells become dysfunctional during COVID-19, showing a loss of thrombomodulin expression related to severe thrombosis and infiltration, and endothelial cell dysfunction might be caused by a pathologic condition in COVID-19 patient lungs rather than a direct infection with SARS-CoV-2.

Funding: This work was supported by the Johns Hopkins University, the American Heart Association, and the National Institutes of Health.

Keywords: COVID-19; SARS-CoV-2; endothelial cell dysfunction; immunothrombosis; thrombomodulin.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Blood Coagulation Disorders / metabolism*
  • Blood Coagulation Disorders / pathology
  • COVID-19 / metabolism*
  • COVID-19 / pathology
  • Down-Regulation*
  • Endothelial Cells / metabolism
  • Endothelial Cells / ultrastructure
  • Endothelium, Vascular / metabolism*
  • Endothelium, Vascular / ultrastructure
  • Female
  • Humans
  • Hypoxia / metabolism*
  • Hypoxia / pathology
  • Lung / metabolism*
  • Lung / ultrastructure
  • Male
  • Middle Aged
  • SARS-CoV-2 / metabolism*
  • Thrombomodulin / biosynthesis*

Substances

  • THBD protein, human
  • Thrombomodulin